Dysfunction or altered expression of Claudin 5 has been linked to various pathological conditions, including stroke, multiple sclerosis, and epilepsy. It is also implicated in the progression of Alzheimer's disease and other neurodegenerative disorders, making it a potential target for therapeutic interventions.
